Issues
Deals
Research
Ledger
About
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 23 · Tue 17 Nov
All issues
Lilly
Every issue covering Lilly.
6 issues
2026-09-29
No. 16
Initiated in Q2. Unregistered at the end of Q3.
TRIALS
DEALS
REGULATORY
LILLY
ATAIBECKLEY
COMPASS
CYBIN
2026-09-22
No. 15
The CVR is an option, and Lilly holds it
DEALS
REGULATORY
TRIALS
LILLY
ATAIBECKLEY
COMPASS
ABBVIE
OTSUKA
2026-09-15
No. 14
Five countries, one regulator.
TRIALS
DEALS
REGULATORY
DEFINIUM
LILLY
ATAIBECKLEY
COMPASS
GH
2026-09-01
No. 12
Lilly’s depression trial went from one approval to four in seven days.
TRIALS
REGULATORY
LILLY
ATAIBECKLEY
ATAI-THERAPEUTICS
2026-08-25
No. 11
Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.
TRIALS
REGULATORY
LILLY
ATAIBECKLEY
BECKLEY-PSYTECH
REGION-SKANE
2026-07-21
No. 7
Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine
DEALS
REGULATORY
LILLY
ATAIBECKLEY